Top

Clinical and Translational Oncology

Published in:

01-09-2017 | Research Article

Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer

Authors: S. Hou, P. Du, P. Wang, C. Wang, P. Liu, H. Liu

Published in: Clinical and Translational Oncology | Issue 9/2017

Abstract

Background

Ovarian cancer is the most lethal gynecologic malignancy worldwide with surgery as the only curative treatment. Long-term overall survival (OS) of ovarian cancer is far from satisfactory, even though significant improvement has been made in post-operative chemotherapy. One of the most important death cause is the chemoresistance due to consecutive chemotherapy. Therefore, understanding the molecular mechanisms involved in ovarian cancer development and identification of novel therapeutic targets are urgently required.

Methods

Immunohistochemical (IHC) staining was used to explore the expression pattern of mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) in tumor tissues from 138 epithelial ovarian cancer (EOC) patients. Clinicopathological data were subjected to Kaplan–Meier survival and Cox multivariate analyses to evaluate the prognostic value of MNK1 in EOC. Overexpression and silencing procedures were performed on OVCAR-5 cells to investigate the mechanisms of MNK1 in regulating EOC development. The anti-tumor effects of CGP57380, a specific MNK inhibitor, were examined by cell viability assay.

Results

Higher MNK1 expression showed significant relationship with advanced FIGO stage and positive lymph node metastasis of EOC. Univariate and multivariate analyses revealed that MNK1 was an independent prognostic factor for OS of EOC patients. In vitro study demonstrated that MNK1 can promote cell proliferation through regulating the phosphorylation level of eukaryotic initiation factor 4E. In addition, inhibition of MNK1 by CGP57380 significantly down-regulated the OVCAR-5 cell viability.

Conclusion

High MNK1 expression in EOC tissues indicates poor clinical outcomes, and MNK1 can act as a potential target for novel chemotherapy development towards EOC.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRefPubMed

Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC, Fasih N. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiogr Rev Publ Radiol Soc N Am Inc. 2011;31(3):625–46. doi:10.1148/rg.313105066.

Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183–203. doi:10.3322/caac.20113.CrossRefPubMedPubMedCentral

Felix AS, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL, et al. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2011;21(5):877–84. doi:10.1097/IGC.0b013e31821a62dd.CrossRef

Hay N. Mnk earmarks eIF4E for cancer therapy. Proc Natl Acad Sci USA. 2010;107(32):13975–6. doi:10.1073/pnas.1008908107.CrossRefPubMedPubMedCentral

Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci J Virtual Libr. 2008;13:5359–73.CrossRef

Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA. 2010;107(32):14134–9. doi:10.1073/pnas.1005320107.CrossRefPubMedPubMedCentral

Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R, et al. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA. 2010;107(32):13984–90. doi:10.1073/pnas.1008136107.CrossRefPubMedPubMedCentral

Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21(24):3232–7. doi:10.1101/gad.1604407.CrossRefPubMedPubMedCentral

10.

Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004;24(15):6539–49. doi:10.1128/mcb.24.15.6539-6549.2004.CrossRefPubMedPubMedCentral

11.

Bell JB, Eckerdt F, Alley K, Magnusson LP, Hussain H, Bi Y, et al. MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. Mol Cancer Res MCR. 2016. doi:10.1158/1541-7786.mcr-16-0172.

12.

Wheater MJ, Johnson PW, Blaydes JP. The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol Ther. 2010;10(7):728–35. doi:10.4161/cbt.10.7.12965.CrossRefPubMedPubMedCentral

13.

Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007;129(6):1065–79. doi:10.1016/j.cell.2007.03.052.CrossRefPubMed

14.

Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N, et al. The Mnks are novel components in the control of TNFα biosynthesis and phosphorylate and regulate hnRNP A1. Immunity. 2005;23(2):177–89. doi:10.1016/j.immuni.2005.06.009.CrossRefPubMed

15.

O’Loghlen A, Gonzalez VM, Salinas M, Martin ME. Suppression of human Mnk1 by small interfering RNA increases the eukaryotic initiation factor 4F activity in HEK293T cells. FEBS Lett. 2004;578(1–2):31–5. doi:10.1016/j.febslet.2004.10.063.CrossRefPubMed

16.

Welnowska E, Castello A, Moral P, Carrasco L. Translation of mRNAs from vesicular stomatitis virus and Vaccinia virus is differentially blocked in cells with depletion of eIF4GI and/or eIF4GII. J Mol Biol. 2009;394(3):506–21. doi:10.1016/j.jmb.2009.09.036.CrossRefPubMed

17.

Bramham CR, Jensen KB, Proud CG. Tuning Specific Translation in Cancer Metastasis and Synaptic Memory: Control at the MNK–eIF4E Axis. Trends Biochem Sci. 2016;41(10):847–58. doi:10.1016/j.tibs.2016.07.008.CrossRefPubMed

18.

Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337–42. doi:10.1038/nature10098.CrossRefPubMed

19.

Jung H, Gkogkas CG, Sonenberg N, Holt CE. Remote control of gene function by local translation. Cell. 2014;157(1):26–40. doi:10.1016/j.cell.2014.03.005.CrossRefPubMedPubMedCentral

20.

Jones RM, MacDonald ME, Branda J, Altherr MR, Louis DN, Schmidt EV. Assignment of the human gene encoding eukaryotic initiation factor 4E (EIF4E) to the region q21-25 on chromosome 4. Somat Cell Mol Genet. 1997;23(3):221–3.CrossRefPubMed

21.

Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 1999;18(1):270–9. doi:10.1093/emboj/18.1.270.CrossRefPubMedPubMedCentral

22.

Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 1997;16(8):1909–20. doi:10.1093/emboj/16.8.1909.CrossRefPubMedPubMedCentral

23.

Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16(12):1472–87. doi:10.1101/gad.995802.CrossRefPubMedPubMedCentral

24.

Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428(6980):332–7. doi:10.1038/nature02369.CrossRefPubMed

25.

Wolf JK, Jenkins AD. Gene therapy for ovarian cancer (review). Int J Oncol. 2002;21(3):461–8.PubMed

26.

Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Roske A, et al. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep. 2008;20(6):1409–17.PubMed

27.

Choi CH, Lee JS, Kim SR, Lee YY, Kim CJ, Lee JW, et al. Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. J Cancer Res Clin Oncol. 2011;137(3):463–9. doi:10.1007/s00432-010-0902-z.CrossRefPubMed

28.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92. doi:10.1056/NEJMoa1105535.CrossRefPubMed

Title: Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer
Authors: S. Hou
P. Du
P. Wang
C. Wang
P. Liu
H. Liu
Publication date: 01-09-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 9/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1646-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2017

The time has come for new models in febrile neutropenia: a practical demonstration of the inadequacy of the MASCC score

Radiotherapy for adrenal gland metastases from hepatocellular carcinoma

Implementation of safeguards to improve patient safety in chemotherapy

Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer

Expression of anoctamin 1 is associated with advanced tumor stage in patients with non-small cell lung cancer and predicts recurrence after surgery

Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer